This Article Full Text Full Text (PDF) An erratum has been published eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nabholtz, J.-M. Articles by Riva, A. Search for Related Content PubMed PubMed Citation Articles by Nabholtz, J.-M. Articles by Riva, A.

Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer?

University of California at Los Angeles, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, USA

Correspondence: Jean-Marc Nabholtz, M.D., University of California at Los Angeles, Cancer Therapy Development Program, Jonsson Comprehensive Cancer Center at UCLA, Breast Cancer International Research Group (BCIRG), 10945 Le Conte Avenue, Los Angeles, California 90095-7077, USA. Telephone: 310-206-8452; Fax: 310-794-0079; e-mail: jean-marc.nabholtz{at}bcirg.com

Among the novel chemotherapeutic drugs introduced in the 1990s, the taxanes have emerged as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant trials proceeded. Docetaxel was shown in several phase III trials to be superior, particularly in terms of survival, for salvaging polychemotherapies after failure of prior chemotherapy, including that with anthracyclines. A benefit of docetaxel was also reported when compared with doxorubicin after failure of alkylating agents. In phase III trials paclitaxel was reported to be as efficacious over 24 hours as doxorubicin 60 mg/m², while paclitaxel was significantly inferior to doxorubicin 75 mg/m² over 3 hours and was close to CMF in another trial. The role of taxanes in combination with anthracyclines in first-line therapy of advanced breast cancer is emerging. Following several phase II studies, a phase III trial showed the significant superiority of docetaxel/doxorubicin (AT) versus doxorubicin/cyclophosphamide (AC) in terms of response and time to progression. In several phase II studies with paclitaxel (3 hours), anthracyclines in the metastatic setting showed high efficacy but produced cardiac toxicity related to a pharmacokinetic interaction between the two agents. This finding led to the implementation of metastatic strategies (phase III trials) aimed at avoiding the pharmacokinetic interaction, while the adjuvant strategies with paclitaxel focused primarily on the sequential approach (AC followed by paclitaxel). In contrast, adjuvant strategies with docetaxel/anthracycline-based programs were implemented following both sequential and combination approaches.

Key Words. Taxane • Anthracycline • Metastatic breast cancer • Doxorubicin • Docetaxel • Adjuvant

This article has been cited by other articles:

				T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995. [Abstract] [Full Text] [PDF]

				J. Tabernero, M. A. Climent, A. Lluch, J. Albanell, J. B. Vermorken, A. Barnadas, A. Anton, C. Laurent, J. I. Mayordomo, N. Estaun, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer Ann. Onc., September 1, 2004; 15(9): 1358 - 1365. [Abstract] [Full Text] [PDF]

				E. Alba, M. Martin, M. Ramos, E. Adrover, A. Balil, C. Jara, A. Barnadas, A. Fernandez-Aramburo, P. Sanchez-Rovira, M. Amenedo, et al. Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study J. Clin. Oncol., July 1, 2004; 22(13): 2587 - 2593. [Abstract] [Full Text] [PDF]

				A. Alexopoulos, M. V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta, and G. Rigatos Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer Ann. Onc., June 1, 2004; 15(6): 891 - 895. [Abstract] [Full Text] [PDF]

				R. Colomer, A. Llombart-Cussac, A. Lluch, A. Barnadas, B. Ojeda, V. Caranana, Y. Fernandez, J. Garcia-Conde, S. Alonso, S. Montero, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain Ann. Onc., February 1, 2004; 15(2): 201 - 206. [Abstract] [Full Text] [PDF]

				J.-M. Nabholtz, C. Falkson, D. Campos, J. Szanto, M. Martin, S. Chan, T. Pienkowski, J. Zaluski, T. Pinter, M. Krzakowski, et al. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial J. Clin. Oncol., March 15, 2003; 21(6): 968 - 975. [Abstract] [Full Text] [PDF]

				R. Paridaens, F. Van Aelst, V. Georgoulias, H. Samonnig, V. Cocquyt, C. Zielinski, H. Hausmaninger, P. Willemse, Y. Boudraa, J. Wildiers, et al. A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer Ann. Onc., March 1, 2003; 14(3): 433 - 440. [Abstract] [Full Text] [PDF]

				D. Miles, G. von Minckwitz, and A. D. Seidman Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer Oncologist, December 1, 2002; 7(90006): 13 - 19. [Abstract] [Full Text] [PDF]

				M. S. Aapro Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001 Oncologist, August 1, 2001; 6(4): 376 - 385. [Abstract] [Full Text] [PDF]